Perhexiline therapy in patients with Hypertrophic Cardiomyopathy

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-000755-15-GB

Enrollment

Registered

2005-05-27

Start date

2005-10-25

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy

Interventions

Product Name: Pexsig Pharmaceutical Form: Tablet INN or Proposed INN: Perxexiline CAS Number: 6724-53-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic non-obstructive hypertrophic cardiomyopathy patients with less than 70% of predicted peak Vo2 and in sinus rhythm Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Abnormal liver function test, Pre-existing peripheral neuropathy, Concomitant use of amiodarone and women of childbearing potential .

Design outcomes

Primary

Measure	Time frame
Main Objective: Main objective :to test whether perhexiline improve exercise capacity(peakVo2) in patients with HCM. ;Secondary Objective: Secondary objectives : symptoms,cardiac and skeletal energitics, exercise cardiac output,diastolic function and ejection fraction. ;Primary end point(s): Peak Vo2	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026